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Abstract
Background: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who
failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on
migraine outcome, negative emotional states and sleep quality in patients with CM.
Methods: A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included.
Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used,
Migraine Disability Assessment Scale.
(MIDAS) scores and Depression, Anxiety and Stress Scale (DASS-21) were evaluated at baseline (visit 1) and 4
consecutive follow up visits, each conducted after OnabotA injection series; at week 12 (visit 2), week 24 (visit 3),
week 36 (visit 4) and week 48 (visit 5) to evaluate change from baseline to follow up.
Results: From baseline to visit 5, significant decrease was noted in least square (LS) mean headache frequency
(from 19.5 to 8.4, p = 0.002), headache severity (from 8.1 to 6.1, p = 0.017), number of analgesics (from 26.9 to 10.4,
p = 0.023) and MIDAS scores (from 67.3 to 18.5, p < 0.001). No significant change from baseline was noted in global
PSOI and DASS-21 scores throughout the study.
Conclusions: Our findings revealed that OnabotA therapy was associated with significant improvement in migraine
outcome leading to decrease in headache frequency and severity, number of analgesics used and MIDAS scores.
While no significant change was noted in overall sleep quality and prevalence of negative emotional states,
patients without negative emotional states at baseline showed improved sleep quality throughout the study.
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Background
Chronic Migraine (CM) is a complex and severely disab-
ling neurological disorder, characterized by occurrence
of headache on ≥15 days per month for >3 months with
at least five attacks fulfilling criteria of migraine without
aura on ≥8 days per month [1].
Having a prevalence of 1–3% documented in
population-based studies [2], CM is considered to be
a more disabling and burdensome disorder than epi-
sodic migraine (EM), as associated with greater
migraine-related disability [3], more frequent hospital
admissions [4–6], poorer health-related quality of life
(HRQoL) [4–7], higher amount of lost work and
household productivity [4–6, 8], and increased risk
for comorbidities [9] and medication overuse [10].
Increased comorbidity between migraine and several
psychiatric conditions has consistently been reported
with higher prevalence of mood and anxiety disorders,
personality disorders and post-traumatic stress disorder
(PTSD) among migraineurs than in the general popula-
tion [11–13]. Also, increased headache frequency was
shown to be correlated with higher rate of depression,
anxiety and post-traumatic stress disorder [5, 14–16].
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Recent studies also indicate a higher prevalence of poor
sleep quality in patients with than without migraine and
association of frequency of migraine headache with poor
sleep quality [17–22].
This seems notable given the association of co-
morbidities with increased burden of CM in terms of
productivity loss, impaired HRQoL, healthcare
utilization and emotional burden5 as well as treatment
complications and poor clinical outcomes [13].
Despite availability of preventive and abortive treat-
ments as the mainstays of treatment for migraines, one-
third of migraine sufferers remain symptomatic due to
frequent partial response to treatment that leads to
physical disability and high risk of medication overuse
[22–24]. Therefore, development of new and effective
therapeutic alternatives is of particular significance in
the management of CM [24, 25].
Onabotulinumtoxin A (OnabotA) recently was discov-
ered to be effective in preventing recurrent migraines in
patients with CM who failed on traditional therapies [22,
26, 27]. Hence, based on data from PREEMPT (Phase 3
REsearch Evaluating Migraine Prophylaxis Therapy) trials
confirming its efficacy in reduction of number of head-
ache days and migraine days in CM patients with favor-
able safety and tolerability [28–31], OnabotA (155–195 U)
is specifically indicated as a prophylactic treatment for
CM in adults [26, 32].
The present study was designed to evaluate the effect of
OnabotA injection series on migraine outcome, negative
emotional states and sleep quality in patients with CM.
Methods
Study population
A total of 190 consecutive patients with CM (mean (SD)
age: 39.3 (10.2) years; 87.9% were female) were included
in this single-center prospective cohort study conducted
between May 2012 and May 2016. After baseline visit at
study enrollment (visit 1), patients were followed up for
48 weeks via 4 consecutive follow up visits each con-
ducted after a new OnabotA injection series; at week 12
(visit 2), week 24 (visit 3), week 36 (visit 4) and week 48
(visit 5), respectively. Most of the patients had a history
of prophylactic treatment for migraine which was either
insufficient or was discontinued due to intolerance.
Written informed consent was obtained from each
subject following a detailed explanation of the objectives
and protocol of the study which was conducted in ac-
cordance with the ethical principles stated in the “Dec-
laration of Helsinki” and approved by the Acibadem
University Clinical Research Ethics Committee.
Study parameters
Data on patient demographics (age, gender), educational
status, diagnosis (CM, CM +medication overuse),
migraine duration (year), family history for migraine,
previous migraine treatments, migraine triggers are col-
lected at baseline visit (visit 1). Data on migraine out-
come [headache frequency and severity, number of
analgesics used and Migraine Disability Assessment
Scale (MIDAS) scores], sleep quality [Pittsburgh sleep
quality index (PSQI)] and negative emotional states [De-
pression, Anxiety, and Stress Scale-21 (DASS-21)] were
evaluated at baseline and follow up visits. Medication
overuse was baseline of simple analgesics on ≥ 15 days.
Follow up period was composed of 4 consecutive visits
each conducted after a new OnabotA injection series; at
week 12 (visit 2), week 24 (visit 3), week 36 (visit 4) and
week 48 (visit 5), respectively. Change from baseline to
follow up was evaluated based on data from visit 1 to
visit 3 (24 weeks) for PSQI, from visit 1 to visit 4
(36 weeks) for DASS-21 scores, while based on data
from visit 1 to visit 5 (48 weeks) for headache frequency
and severity, number of analgesics used and MIDAS
score. Data at visit 2, visit 3, visit 4 and visit 5 refer to
changes in parameters observed after 1st, 2nd, 3rd and 4th
OnabotA injection series, respectively.
Diagnosis of CM
CM was diagnosed based on International Classification
of Headache Disorders (third revision) (ICHD-3 beta)
diagnostic criteria that require headache occurring on
≥15 days per month for >3 months with at least five at-
tacks fulfilling criteria of migraine without aura on
≥8 days per month [1].
OnabotA injection series
Administration of OnabotA was performed as 31 fixed-
site, fixed-dose intramuscular injections applied at seven
specified head and neck muscle points every 12 weeks
for a minimum of 24 weeks (2 treatment cycles) accord-
ing to injection scheme proposed in the PREEMPT stud-
ies [28, 29, 33]. We additionally administered OnabotA
among occipitalis, temporalis or trapezius muscles using
a follow-the-pain strategy.
MIDAS
The MIDAS is a 5-question tool to quantitatively evalu-
ate the headache-related disability in terms of the num-
ber of days in the past 3 months and activity limitations
due to migraine. MDAS was developed by Stewart
et al.[34] and validated and checked for reliability for
Turkish by Ertas et al. [35] The score obtained can be
graded as follows: grade I (0 to 5 days) indicative of little
or no disability; grade II (6 to 10 days), mild disability;
grade III (11 to 20 days), moderate disability; and grade
IV (greater than 21 days), severe disability.
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DASS-21
The DASS-21 is a 21-item questionnaire which includes
three self-report scales designed to measure the negative
emotional states of depression, anxiety and stress. The
Depression scale includes items that measure symptoms
typically associated with dysphoric mood (e.g., sadness
or worthlessness). The Anxiety scale includes items that
are primarily related to symptoms of physical arousal,
panic attacks, and fear (e.g., trembling or faintness). Fi-
nally, the Stress scale includes items that measure symp-
toms such as tension, irritability, and a tendency to
overreact to stressful event. Each item is scored on a 4-
point scale (0 = Did not apply to me at all, to 3 = Applied
to me very much or most of the time) to rate the extent
to which they have experienced each state over the past
week. Sum of the score of each item reveals the total
score with higher scores indicating greater levels of dis-
tress. Each state is categorized into normal/mild/moder-
ate/severe/extremely severe based on cut-off scores
recommended for depression (0-4/5-6/7-10/11-13/14+),
anxiety (0-3/4-5/6-7/8-9/10+) and stress (0-7/8-9/10-12/
13-16/17+) [36–38]. Psychometric properties of the
Turkish version of the DASS was studied by Hekimoglu
et al. and DASS was shown to be an excellent instru-
ment for measuring features of depression, hyperarousal,
and tension in clinical groups [39].
PSQI
The PSQI, used to assess sleep quality, was developed by
Buysse et al. [40] and validated and checked for reliabil-
ity for Turkish by Agargun et al. [41]. The scale consists
of 24 items; eighteen items are scored and yield seven
component scores. Each component is scored between 0
and 3 and the total of these scores gives the scale score.
The total score ranges between 0 and 21 and the higher
the score is, the worse the sleep quality. A total score
under 5 indicates ‘good sleep quality’, while a score above
5 shows ‘poor sleep quality’.
Statistical analysis
Statistical analysis was made using IBM SPSS Statistics
(IBM Corp. Released 2012. IBM SPSS Statistics for Win-
dows, Version 21.0, Armonk, NY: IBM Corp). Change
over time analysis was based on number of patients with
available data on both baseline (visit 1) and follow-up
visits (visit 2 to 5), and performed via repeated measures
variance analysis and McNemar test for continuous and
categorical variables, respectively. Since time to follow
up visits showed variability among patients, change over
time analysis of continuous variables were adjusted for
time (visit 2 = 12 weeks; visit 3 = 24 weeks; visit 4 =
36 weeks; visit 5 = 48 weeks). No specific procedure was
defined for missing data. Data were expressed as n(%),
mean (standard deviation; SD), median (inter-quartile
range, IQR) and mean (lower and upper boundaries of
95% confidence interval; CI) where appropriate. p < 0.05
was considered statistically significant.
Results
Patient disposition and baseline characteristics
Of 190 patients; 101 (53.2%) attended at least one
follow-up visit. Overall 98 (51.6%) patients attended visit
2, 58 (30.5%) patient visit 3, 34 (17.9%) patients visit 4,
and 20 (10.5%) patients attend visit 5, which were per-
formed at week 12, week 24, week 36 and week 48,
respectively.
During the study period overall four injection series
were applied per patient within a total treatment time of
48 weeks (median (IQR) 62.4 (53.8–85.2) weeks).
Most of the participants were university graduates
(41.1%), diagnosed with CM per se (48.9%) without trig-
gers (76.8%) and for median (IQR) 3.0 (1.0–10.0) years.
Family history for migraine was evident in 28.9% of pa-
tients; while most common previous medication was
non steroid anti-inflammatory drugs (88.4%). Medication
overuse was evident in 76.2% of patients (Table 1).
Migraine outcome
Overall, mean (SD; median) headache frequency was
17.9 (7.8;15.0) at visit 1 and 6.8 (5.1;5.0) at visit 5. Me-
dian (IQR) headache severity scores were 8.0 (7.0–9.0)
and 7.0 (5.0–7.0), number of analgesics used were 20.0
(15.0–30.0) and 5.5 (2.0–10.0) and MIDAS scores were
57.0 (35.5–75.0) and 10.0 (2.0–15.0) at visit 1 and visit 5,
respectively (Table 2).
Mean headache frequency was significantly decreased
from LS mean 19.5 at visit 1 to 6.8 at visit 2 (p < 0.001),
to 7.5 at visit 3 (p < 0.001), to 5.4 at visit 4 (p < 0.001)
and to 8.4 at visit 5 (p = 0.002) (Table 3).
Mean headache severity was significantly decreased
from 8.1 at baseline to 6.2 at visit 2 (p < 0.001), to 5.8 at
visit 3 and visit 4 (p < 0.001 for each) and to 6.1 at visit 5
(p = 0.017) (Table 3).
Mean number of analgesics used was significantly de-
creased from 26.9 at baseline to 7.8 at visit 2 (p < 0.001),
to 8.7 at visit 3 (p < 0.001), to 5.1 at visit 4 (p < 0.001)
and to 10.4 at visit 5 (p = 0.023) (Table 3).
Mean MIDAS score was decreased significantly from
67.3 at baseline to 17.4 at visit 2 (p < 0.001), to 15.3 at
visit 3 (p < 0.001), to 9.3 at visit 4 (p < 0.001) and to 18.5
at visit 5 (p < 0.001) (Table 3).
Negative emotional states
DASS-21 revealed normal scores for depression (60.0,
52.0, 60.0 and 57.1%), anxiety (56.5, 51.5, 41.2 and
57.1%) and stress (51.8, 54.5, 29.4 and 42.9%) in similar
percentage of patients at visit 1, visit 2, visit 3 and visit
4, respectively (Table 4).
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Mild-to-moderate depression (29.4% at visit 1, 28.6%
at visit 4), anxiety (25.9% at visit 1, 28.6% at visit 4) and
stress (35.3% at visit 1, 42.9% at visit 4) was evident in
remarkable percentage of patients throughout the study
period, while severe-to-extremely severe depression
(10.6% at visit 1, 14.3% at visit 4), anxiety (17.7% at visit
1, 14.3% at visit 4) and stress (12.9% at visit 1, 14.3% at
visit 4) were also noted in less than 15% of patients.
Based on patients with valid data for both baseline and
follow up visits, no significant change was noted in
percentage of patients categorized to have normal anx-
iety, depression and stress scores at each follow up visit
(Table 5).
Sleep quality
Overall, median (IQR) global score at visit 1 and visit 5
were 9.0 (5.0–12.0) and 4.0 (1.0–7.0), respectively
(Table 6).
Based on patients with valid data for both baseline and
follow up visits, no significant difference was noted in
global scores and thus overall sleep quality from baseline
to visit 2 or visit 3. Considering component scores,
mean (95% CI lower bound-upper bound) scores for
subjective sleep quality (from baseline 1.7 (1.4–2.0) to
1.1 (0.8–1.5) at visit 2, p = 0.002), sleep latency (from
baseline 1.7 (1.4–2.0) to 1.1 (0.8–1.5 at visit 2, p = 0.002)
and sleep disturbance (from baseline 1.7 (1.4–2.0) to 1.2
(0.9–1.6) at visit 2, p = 0.013) components improved sig-
nificantly from baseline to visit 2 (Table 7).
Sleep quality with respect to DASS-21 scores
Good sleep quality was noted at visit 1, visit 2 and visit 3
34.3, 40.0 and 57.1% of patients with normal depression
scores at visit 1, in 38.7, 45.5 and 50.0% of patients with
normal anxiety scores at visit 1, and in 33.3, 46.2 and
60.0% of patients with normal stress scores at visit 1, re-
spectively (Table 8).
Adverse events and treatment alterations under OnabotA
therapy
OnabotA therapy was associated with minor and tem-
porary side effects (e.g., asymmetry of the position of the
eyebrows and neck ache) in some patients. In one pa-
tient who has a very thin cervical region, dysphagia and
difficulty in swallowing appeared while regressed after
the third week of therapy. Treatment was continued in
this patient with omission of further injections to the
cervical area.
Treatment alterations included discontinuation of
OnabotA therapy (n = 2), addition of antiepileptic (n = 3)
or SSRI (n = 9) medications and discontinuation of on-
going antiepileptic (n = 3) or SSRI (n = 1) medications.
Discussion
Our findings revealed that administration of four Ona-
botA injection series over 48 weeks in chronic migrai-
neurs was associated with a significant improvement in
all migraine parameters including headache frequency
and severity, number of analgesics used and MIDAS
scores, while no significant change from baseline was
noted in overall sleep quality and prevalence of negative
emotional states. Patients without negative emotional
states at baseline showed improved sleep quality
throughout the study.
Table 1 Patient characteristics






Primary school 9 (4.7)
High school 22 (11.6)
University 78 (41.1)
MSc & PhD 9 (4.7)
Missing 72
Diagnosis n(%)
Chronic migraine 93 (48.9)
Chronic migraine + medication overuse 97 (51.1)
Migraine duration (year), median (IQR) 3.0 (1.0–10.0)




Previous migraine treatments, n(%)
Non-steroid anti-inflammatory drugs 168 (88.4)
Antiepileptic 61 (32.1)
Antidepressants 57 (30.0)
Beta blockers 24 (12.6)
Calcium channel blockers 1 (0.5)
Migraine triggers, n(%)
None 146 (76.8)
At least one trigger 44 (23.2)
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Significant reduction in monthly headache frequency,
headache severity, number of analgesics used and
MIDAS scores in our cohort support the efficacy of
OnabotA in reduction of the frequency, intensity, and
duration of chronic migraines as well as decreasing
medication overuse among CM patients who failed on
traditional preventive therapies [22, 25–27, 42–44].
Reduction in MIDAS scores, indicating lesser amount
of lost work and personal time due to migraine [6], after
OnabotA therapy in our cohort seems notable given that
a day lived with severe migraine is considered to be as
disabling as a day lived with dementia, quadriplegia or
acute psychosis and more disabling than blindness, para-
plegia, angina or rheumatoid arthritis [4, 45, 46].
CM has been associated with a high intake of abortive
medications with estimated analgesic overuse in 50–80%
of patients with CM that may lead to the development
of medication overuse headache (MOH) [47]. Given the
similar rates of medication overuse (76.2%) in our cohort
at baseline, reduction in in number of analgesics used
starting from the first injection and consistently
throughout the study period emphasizes the potential
role of OnabotA therapy in prevention of MOH via
headache episode reduction [25, 42, 48–50].
In terms of monthly headache frequency, headache se-
verity, number of analgesics used and MIDAS scores our
findings support the association of OnabotA therapy
with rapid improvement in migraine parameters usually
after the first session as reported in past studies [26, 27,
30, 51–53].
The rapid improvement of migraine parameters after
OnabotA therapy has been linked to the combined
pharmacological and the placebo effect at the beginning
of the treatment [51, 52], while increased benefit offered
via repeated OnabotA injections over time is associated
with a prophylactic cumulative effect [31, 54]. Also, pa-
tients who respond well to therapy early have been sug-
gested to maintain and continue these reductions over at
least 2 years [27, 55–57], while limited data are available
on long-term efficacy of OnabotA therapy with evalu-
ation of efficacy only up to1 year in most of clinical trials
[42, 44, 50].
Alike to our findings, use of four OnabotA injec-
tions over 48 weeks in CM patients was reported to
be associated with significant improvement in
monthly headache days, migraine days and medication
days that continued throughout the entire study
period [42]. Nonetheless, in a longer-term study with
seven OnabotA injections in CM patients, based on a
decrease in initial efficacy of OnabotA therapy after
the third injection, authors concluded that actual im-
provement and amelioration of daily headache under
OnabotA therapy needs several months to be consoli-
dated [52].
Long-term efficacy of OnabotA in CM patients has re-
cently been evaluated in some studies based on adminis-
tration of OnabotA therapy for 2 years [25], 4 years [43]
and 7–9 injections series [52, 58]. However, while find-
ing are consistent regarding long-term efficacy of ther-
apy with no serious adverse events in responders, they
varied in terms of durability of benefit, non-responder
rates and the length and necessity of withdrawal of treat-
ment at scheduled times [25, 43, 52, 58].
Both depression and anxiety have been proposed to
be a risk factor for migraine chronification [13, 59,
60], while migraine headache frequency and headache
severity were reported to be associated with higher
rate of depression and anxiety disorders [4, 5, 14, 61].
Accordingly, identification of abnormal scores for de-
pression, anxiety and stress in almost half of patients
in our cohort is in line with higher rates of self-
reported mood and anxiety disorders in patients with
CM as compared with general population and EM pa-
tients [4, 5, 13, 14] with more than 40.0% of CM pa-
tients to meet criteria for moderate to severe anxiety
and depression [4, 13].
Reduction in headache frequency via 24-week OnabotA
therapy was reported to be associated with reduction in
depression (via Beck Depression Inventory-II) and anxiety
scores (Generalized Anxiety Disorder-7 scale) in a past
among CM patients [62]. In fact, even a direct effect of
OnabotA injection in amelioration of depressive symp-
toms has been suggested that probably occur via the facial
feedback mechanism with consideration of OnabotA as a
Table 2 Overall headache frequency and severity, analgesic use and MIDAS scores
Headache frequency Headache severity Number of analgesics MIDAS score
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Visit 1 (n = 185) 15.0(12.0–25.0) 8.0(7.0–9.0) 20.0(15.0–30.0) 57.0(35.5–75.0)
Visit 2 (n = 89) 5.0(3.0–10.0) 7.0(5.0–8.0) 5.0(2.0–10.0) 10.5(1.5–23.0)
Visit 3 (n = 55) 5.0(2.0–10.0) 6.0(5.0–7.0) 4.0(1.0–10.0) 9.0(3.0–24.0)
Visit 4 (n = 31) 4.0(1.0–9.0) 6.0(5.0–8.0) 4.0(1.0–10.0) 6.0(2.0–10.0)
Visit 5 (n = 19) 5.0(2.0–10.0) 7.0(5.0–7.0) 5.5(2.0–10.0) 10.0(2.0–15.0)
IQR inter-quartile range, n patient count without missing data
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safe adjunctive treatment to pharmacotherapy for major
depressive disorder [63].
In this regard, it seems notable that despite significant
reductions obtained via OnabotA therapy in both
monthly headache frequency and headache severity in
our cohort, no significant change from baseline occurred
in depression, anxiety and stress rates throughout the
study.
High rates of negative emotional states regardless of
the ongoing OnabotA therapy in our patients seems not-
able given the impact of psychiatric comorbidities on
disease prognosis, treatment, and clinical outcomes and
higher prevalence of severe headache-related disability,
headache impact and poor quality of life in migraineurs
with than without psychiatric comorbidities [11, 13, 64].
Hence our findings emphasize consideration of co-
morbid psychiatric disorders in diagnostic evaluation
and formulation of treatment plan in CM patients, being
aware of the likely negative impact of co-morbid psychi-
atric disorder on treatment outcomes, adherence and
quality of life [5, 14, 65].
Identification of poor sleep quality at baseline in 72.9%
of our patients seems consistent with high prevalence
(30–79%) of co-morbid poor sleep quality among
migraineurs [20, 66–68], particularly in those with 8 or
more migraine days per month [17]. Higher prevalence
of poor sleep quality was also noted in patients with mi-
graine compared to those without migraine [17–21],
while high migraine frequency was shown to correlate
with poor sleep quality and a higher prevalence of poor
sleepers in chronic migraineurs [21].
In a past study on the effects of OnabotA on jaw
motor events during sleep in sleep bruxism patients, no
significant change from baseline was noted in usual
sleep variables such as sleep efficiency, arousal index,
sleep stages, or awakenings per hour during follow-up
recordings [69].
Similarly, our findings revealed no direct effect of
OnabotA injection on overall sleep quality at week 12
and week 24, while significant improvement in subject-
ive sleep quality, sleep latency and sleep disturbance at
week 12. This seems notable given the reported asso-
ciation of higher migraine frequency with higher
scores for certain domains of PSQI such as “cannot
get to sleep within 30minutes,” “wake up in the mid-
dle of the night or early morning,” and “bad dreams”
among migraineurs [21].
Sleep-related migraine is considered to be associated
with a more severe and disabling clinical course given
the increased mean attack severity and monthly use of
Table 4 DASS-21 anxiety, depression and stress scores at study visits
DASS-21-Depression score, n (%) DASS-21-Anxiety score, n (%) DASS-21-Stress score, n (%)
Severity Visit 1 Visit 2 Visit 3 Visit 4 Visit 1 Visit 2 Visit 3 Visit 4 Visit 1 Visit 2 Visit 3 Visit 4
Normal 51 (60.0) 13 (52.0) 9 (60.0) 4 (57.1) 48 (56.5) 17 (51.5) 7 (41.2) 4 (57.1) 44 (51.8) 18 (54.5) 5 (29.4) 3 (42.9)
Mild 10 (11.8) 6 (24.0) 2 (13.3) 0 (0) 9 (10.6) 5 (15.2) 3 (17.6) 1 (14.3) 14 (16.5) 6 (18.2) 5 (29.4) 1 (14.3)
Moderate 15 (17.6) 2 (8.0) 3 (20.0) 2 (28.6) 13 (15.3) 5 (15.2) 6 (35.3) 1 (14.3) 16 (18.8) 5 (15.2) 6 (35.3) 2 (28.6)
Severe 6 (7.1) 3 (12.0) 1 (6.7) 0 (0) 10 (11.8) 4 (12.1) 0 (0) 0 (0) 7 (8.2) 4 (12.1) 1 (5.9) 1 (14.3)
Extremely severe 3 (3.5) 1 (4.0) 0 (0) 1 (14.3) 5 (5.9) 2 (6.1) 1 (5.9) 1 (14.3) 4 (4.7) 0 (0) 0 (0) 0 (0)
Total 85 (100) 25 (100) 15 (100) 7 (100) 85 (100) 33 (100) 17 (100) 7 (100) 85 (100) 33 (100) 17 (100) 7 (100)
Table 3 Change in severity, analgesic use, MIDAS scores and headache frequency at follow-up visits
Headache severity Number of analgesics MIDAS score Headache frequency
Baseline n 89 80 66 89
LS mean 8.1 26.9 67.3 19.5
Week 12 n 89 80 66 89
LS mean (p) 6.2 (<0.001) 7.8 (<0.001) 17.4 (0.001) 6.8 (p < 0.001)
Week 24 n 52 50 47 55
LS mean (p) 5.8 (<0.001) 8.7 (<0.001) 15.3 (<0.001) 7.5 (<0.001)
Week 36 n 31 28 24 30
LS mean (p) 5.8 (<0.001) 5.1 (<0.001) 9.3 (<0.001) 5.4 (<0.001)
Week 48 n 19 18 17 19
LS mean (p) 6.1 (0.017) 10.4 (0.023) 18.5 (<0.001) 8.4 (0.002)
LS mean least square mean, n patient count with valid data at each visit, P p value of repeated measures variance analysis with reference to baseline
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symptomatic drugs in patients with than without sleep
related migraine despite similar monthly headache fre-
quency [70].
Although data on sleep quality are available for only
two OnabotA injections in our cohort, given that pa-
tients without negative emotional states at baseline
showed improved sleep quality throughout the study,
maintenance of co-morbid negative emotional states
throughout the study seems to be associated with lack of
improvement in overall sleep quality, despite signifi-
cantly decreased migraine frequency.
Nonetheless, it should also be noted that while the
presence of negative emotional states such as depression
was reported to be reciprocally associated with poor
sleep quality [66, 71] and migraine history and comorbid
anxiety and depression were shown as predictors of
sleep quality [20] in some studies, poor sleep quality was
shown to be associated uniquely with migraine itself, re-
gardless of comorbid depression, anxiety or sleep disor-
ders in other studies, particularly among EM patients
[17, 44, 72, 73].
Certain limitations to this study should be considered.
First, due to observational nature, non-randomized allo-
cation and thereby the likelihood of main selection bias
and confounding is possible. Second, although provide
data on real-life clinical practice, potential lack of
generalizability seems another important limitation due
to single-center design of the study. Third, lack of inter-
vention considering timing and number of follow up
visits in accordance with the observational nature caused


































9.0 (5.0–12.0) 16 (27.1) 43 (72.9) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 2.0 (1.0–2.0) 0.0 (0.0–1.0) 1.0 (0.0–2.0)
Visit 2
(n = 28)
7.0 (3.0–9.5.0) 11 (39.3) 17 (60.7) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (0.0–2.0) 0.5 (0.0–2.0) 1.0 (1.0–2.0) 0.0 (0.0–1.0) 1.0 (0.0–2.0)
Visit 3
(n = 14)
10.0 (5.0–15.0) 4 (28.6) 10 (71.4) 2.0 (1.0–2.0) 2.0 (0.0–2.0) 2.0 (1.0–3.0) 1.5 (1.0–2.0) 2.0 (1.0–2.0) 0.0 (0.0–0.0) 2.0 (0.0–2.0)
Visit 4
(n = 7)
8.0 (7.0–15.0) 1 (14.3) 6 (85.7) 1.0 (1.0–2.0) 1.0 (0.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0) 0.0 (0.0–2.0) 2.0 (1.0–2.0)
Visit 5
(n = 3)
4.0 (1.0–7.0) 2 (66.7) 1 (33.3) 1.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 1.0 (1.0–2.0) 0.0 (0.0–0.0) 1.0 (0.0–2.0)
IQR inter-quartile range (percentile 25 – percentile 75), SD standard deviation, n patient count without missing data
Table 5 Change in DASS-21 anxiety, depression and stress scores from baseline at study visits
Severity, n (%) Change at visit 2 Change at visit 3 Change at visit 4
DASS-21-Depression score Visit 1 Visit 2 Visit 1 Visit 3 Visit 1 Visit 4
Normal 14 (56.0) 13 (52.0) 8 (53.3) 9 (60.0) 4 (57.1) 4 (57.1)
Abnormal 11 (44.0) 12 (48.0) 7 (46.7) 6 (40.0) 3 (42.9) 3 (42.9)
Total 25 (100) 25 (100) 15 (100) 15 (100) 7 (100) 7 (100)
P valuea 1.000 1.000 1.000
DASS-21-Anxiety score Visit 1 Visit 2 Visit 1 Visit 3 Visit 1 Visit 4
Normal 18 (54.5) 17 (51.5) 7 (41.2) 7 (41.2) 3 (42.9) 4 (57.1)
Abnormal 15 (45.5) 16 (48.5) 10 (58.8) 10 (58.8) 4 (57.1) 3 (42.9)
Total 33 (100) 33 (100) 17 (100) 17 (100) 7 (100) 7 (100)
P valuea 1.000 1.000 1.000
DASS-21-Stress score Visit 1 Visit 2 Visit 1 Visit 3 Visit 1 Visit 4
Normal 18 (54.5) 18 (54.5) 4 (23.5) 5 (29.4) 3 (42.9) 3 (42.9)
Abnormal 15 (45.5) 15 (45.5) 13 (76.5) 12 (70.6) 4 (57.1) 4 (57.1)
Total 33 (100) 33 (100) 17 (100) 17 (100) 7 (100) 7 (100)
P valuea 1.000 1.000 1.000
aMcNemar test Comparisons for visit 5 is not performed due to small number patients with valid data
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relatively limited follow-up data and the frequency of pa-
tient visits to be not uniform with considerable loss to
follow up rate challenging analysis of sleep and mood
variables. Fourth, analysis of data on negative emotional
states and sleep quality were based on self-report rather
than objective measures. However, our analysis was
based on use of validated questionnaires along with evi-
dence on high concordance between self-report instru-
ments and clinical diagnosis of psychiatric disorders
[13]. Lack of follow up data on sleep quality after second
OnabotA injection, lack of data on inter-individual varia-
tions in headache characteristics with likely impact on
therapeutic response as well as lack of data on adverse
events are other limitations which otherwise would ex-
tend the knowledge achieved in the current study.
Conclusions
In conclusion, our findings in a cohort of chronic
migraineurs revealed that OnabotA injection was associ-
ated with significant improvement in migraine outcome
Table 8 Sleep quality with respect to DASS-21 anxiety, depression and stress scores
Visit 1 Visit 2 Visit 3
good SQ poor SQ Total good SQ poor SQ Total good SQ poor SQ Total
n(%)
DASS 21-depression score
Normal 12 (34.3) 23 (65.7) 35 (100) 4 (40.0) 6 (60.0) 10 (100) 4 (57.1) 3 (42.9) 7 (100)
Abnormal 4 (16.7) 20 (83.3) 24 (100) 2 (22.2) 7 (77.8) 9 (100) 0 (0) 6 (100) 6 (100)
Total 16 (27.1) 43 (72.9) 59 (100) 6 (31.6) 13 (68.4) 19 (100) 4 (30.8) 9 (69.2) 13 (100)
DASS 21-anxiety score
Normal 12 (38.7) 19 (61.3) 31 (100) 5 (45.5) 6 (54.5) 11 (100) 3 (50.0) 3 (50.0) 6 (100)
Abnormal 4 (14.3) 24 (85.7) 28 (100) 3 (25.0) 9 (75) 12 (100) 1 (14.3) 6 (85.7) 7 (100)
Total 16 (27.1) 43 (72.9) 59 (100) 8 (34.8) 15 (65.2) 23 (100) 4 (30.8) 9 (69.2) 13 (100)
DASS 21-stress score
Normal 10 (33.3) 20 (66.7) 30 (100) 6 (46.2) 7 (53.8) 13 (100) 3 (60.0) 2 (40.0) 5 (100)
Abnormal 6 (20.7) 23 (79.3) 29 (100) 2 (20) 8 (80) 10 (100) 1 (12.5) 7 (87.5) 8 (100)
Total 16 (27.1) 43 (72.9) 59 (100) 8 (34.8) 15 (65.2) 23 (100) 4 (30.8) 9 (69.2) 13 (100)
SQ sleep quality
Visit 4 to 5 was not evaluated because of small number of data
Table 7 Change in PSQI scores at follow up visits















Mean (95% CI) n(%) Mean (95% CI)
Visit 2
(week 12)
na 25 28 24 24 24 24 24 24 24
baseline 9.5(7.8;11.3) good 9 (32.1) 1.7(1.4;2.0) 1.7(1.4;2.0) 1.3(0.8;1.8) 1.4(0.9;2.0) 1.7(1.4;2.0) 0.6(0.1;1.0) 1.4(0.8;1.9)
poor 19 (67.9)
current 8.0(5.8;10.1) good 11 (39.3) 1.1(0.8;1.5) 1.1(0.8;1.5) 1.3(0.9;1.8) 1.3(0.7;1.9) 1.2(0.9;1.6) 0.7(0.2;1.2) 1.0(0.6;1.4)
poor 17 (60.7)
p value 0.1851 0.7272 0.0021 0.0021 0.8241 0.7241 0.0131 0.5311 0.1921
Visit 3
(week 24)
na 13 13 13 13 13 13 13 13 13
baseline 9.4(6.8;12.1) good 3 (21.4) 1.8(1.3;2.3) 1.8(1.3;2.3) 1.3(0.5;2.1) 1.6(0.8;2.4) 1.8(1.4;2.2) 0.4(−0.;1.2) 1.3(0.3;2.4)
poor 11 (78.6)
current 10.5(6.0;15.0) good 4 (28.6) 1.7(1.2;2.2) 1.7(1.2;2.2) 1.6(0.6;2.6) 1.6(0.7;2.4) 1.8(1.1;2.4) 0.9(−0.1;1.8) 1.7(0.8;2.5)
poor 10 (71.4)
p value 0.5311 1.0002 0.5901 0.5901 0.5701 0.9401 0.8821 0.2781 0.2051
CI confidence interval
anumber of patients without missing data (data available for both baseline and the specific follow up visit)
1Repeated measures variance analysis, 2McNemar test. Comparisons for visit 4 and, visit 5 could not be performed due to small number patients with valid data
Values in bold indicate statistical significance (p <0.05)
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leading to decrease in headache frequency and severity,
number of analgesics used and MIDAS scores. While no
significant change was noted in overall sleep quality and
prevalence of negative emotional states with OnabotA
injections, patients without negative emotional states at
baseline showed improved sleep quality throughout the
study. There is a need for future larger-scale long-term
longitudinal studies addressing the durability as well as
predictors of efficacy of OnabotA in CM patients.
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